Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatment of human African trypanosomiasis. Pyrazole sulfonamide (DDD85646), a potent inhibitor of TbNMT, has been identified in previous studies; however, poor central nervous system exposure restricts its use to the haemolymphatic form (stage 1) of the disease. In order to identify new chemical matter, a fragment screen was carried out by ligand-observed NMR spectroscopy, identifying hits that occupy the DDD85646 binding site. Crystal structures of hits from this assay have been obtained in complex with the closely related NMT from Leishmania major, providing a structural starting point for the evolution of novel chemical matter.</p
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (H...
Leishmaniasis is one of the neglected diseases that remain in need for pharmacological alternatives....
Previous research has provided pre-clinical validation for inhibition of the enzyme N-myristoyltrans...
Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatm...
The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically a...
*S Supporting Information ABSTRACT: Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attracti...
The leishmaniases are a spectrum of global diseases of poverty associated with immune dysfunction an...
ABSTRACT: Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatmen...
Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment...
<div><p>Inhibition of <em>N</em>-myristoyltransferase has been validated pre-clinically as a target ...
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), c...
N-Myristoyltransferase (NMT) is a potential drug target in Leishmania parasites. Scaffold-hopping fr...
The leishmaniases, caused by Leishmania species of protozoan parasites, are neglected tropical disea...
Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leish...
Inhibitors of Leishmania <i>N</i>-myristoyltransferase (NMT), a potential target for the treatment o...
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (H...
Leishmaniasis is one of the neglected diseases that remain in need for pharmacological alternatives....
Previous research has provided pre-clinical validation for inhibition of the enzyme N-myristoyltrans...
Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attractive therapeutic target for the treatm...
The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically a...
*S Supporting Information ABSTRACT: Trypanosoma brucei N-myristoyltransferase (TbNMT) is an attracti...
The leishmaniases are a spectrum of global diseases of poverty associated with immune dysfunction an...
ABSTRACT: Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatmen...
Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment...
<div><p>Inhibition of <em>N</em>-myristoyltransferase has been validated pre-clinically as a target ...
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), c...
N-Myristoyltransferase (NMT) is a potential drug target in Leishmania parasites. Scaffold-hopping fr...
The leishmaniases, caused by Leishmania species of protozoan parasites, are neglected tropical disea...
Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leish...
Inhibitors of Leishmania <i>N</i>-myristoyltransferase (NMT), a potential target for the treatment o...
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (H...
Leishmaniasis is one of the neglected diseases that remain in need for pharmacological alternatives....
Previous research has provided pre-clinical validation for inhibition of the enzyme N-myristoyltrans...